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Abstract
Background: Cellulite is a widespread problem involving females’ buttocks and thighs based on the female
specific anatomy. Given the higher number of fat cells stored in female fatty tissue in contrast to males, and the
aging process of connective tissue leads to an imbalance between lipogenesis and lipolysis with subsequent large
fat cells bulging the skin. In addition, microcirculatory changes have been suggested, however remain largely
unknown in a controlled clinical setting. We hypothesize that the combination of extracorporeal shockwave and a
daily gluteal muscle strength program is superior to the gluteal muscle strength program alone in cellulite.
Methods/Design: Study design: Randomized-controlled trial. IRB approval was granted at Hannover Medical
School, Germany on May 22, 2009. For allocation of participants, a 1:1 ratio randomization was performed using
opaque envelopes for the concealment of allocation. Reporting: according to CONSORT 2010. Eligible patients were
females aged 18 or over and 65 or younger with cellulite with documented cellulite 1°-4° according to the
Nürnberger score. Exclusion criteria were suspected or evident pregnancy, no cellulite, no informed consent or age
under 18 years or above 65 years. Patients were recruited by advertisements in local regional newspapers and via
the Internet. Analysis: Intention-to-treat. Outcome parameters: a) Photonumeric severity scale, b) Nürnberger Score,
c) circumference measurements, d) capillary blood flow, e) tissue oxygen saturation, f) postcapillary venous blood
flow. Intervention group: Six sessions of extracorporeal focused shock wave for six sessions (2000 impulses, 0,25
mJ/m2 every 1-2 weeks) at both gluteal and thigh regions plus a specific gluteal strength exercise training. Control
group: Six sessions of sham extracorporeal focused shock wave for six sessions (2000 impulses, 0,01 mJ/m2 every
1-2 weeks) at both gluteal and thigh regions plus a specific gluteal strength exercise training. Follow-up: 12 weeks.
Blinding was achieved for all participants enrolled in the trial, the photograph taking the digital images for the
primary outcome measure, the two assessors of the outcome measures, all additional health care providers and for
the analyst from the biometrical department. Only one researcher (BJ) was aware of the group assignment
performing the randomisation and the extracorporeal shock wave therapy.
Discussion: This randomised-controlled trial will provide much needed evidence on the clinical effectiveness of
focused extracorporal shock wave therapy as an adjunct to gluteal strength training in females suffering cellulite.
ClinicalTrials.gov identifier: NCT00947414.
Background
Given the fact that publishing study protocols might
improve registration, reporting as well as recruitment
[1], we present our randomized-controlled trial entitled
“CelluShock-2009 (ClinicalTrials.gov NCT00947414) in
the following.
Cellulite is a widespread problem involving females’
buttocks and thighs based on the female specific
anatomy. Given the higher number of fat cells stored in
female fatty tissue in contrast to males, and the aging
process of connective tissue leads to an imbalance
between lipogenesis and lipolysis with subsequent large
fat cells bulging the skin. In addition, microcirculatory
changes have been suggested, however remain largely
unknown in a controlled clinical setting.
Non-randomized clinical data suggest that extracor-
poral shock wave therapy applied as acoustic wave ther-
apy is beneficial in terms of improved skin elasticity and
revitalizing dermis in cellulite [2,3].
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effect of extracorporeal shock wave therapy on cellulite
with various outcome measures (Table 1).
Recently, a small size (n = 25) randomised-controlled
trial with large confidence intervals has been published
[7]. Six sessions over four weeks using the D-ACTOR®
200 by Storz Medical improved depressions, elevations,
roughness, and elasticity within three months. However,
to date we do not have any evidence regarding the effect
of gluteal home-based strength training with or without
extracorporeal shockwave therapy on the clinical out-
come in cellulite in terms of digital images, microcircu-
lation and patient-self-reported assessment.
Hypothesis
The combination of extracorporeal shockwave and a
daily gluteal muscle strength program is superior to the
gluteal muscle strength program alone in cellulite.
Methods/Design
The study protocol is composed according to the most
recent CONSORT 2010 recommendations for trans-
parent reporting of randomised-controlled trials http://
www.consort-statement.org [8]. While the group
stressed, that “CONSORT does not include recommen-
dations for designing, conducting, and analyzing trials“
[9] we believe that authors will thoroughly benefit
from the very beginning of planning RCTs from
the consideration of the items addressed in the
recommendations.
Ethics and Registration
This RCT was approved on May 22, 2009 at the ethics
(IRB) at Hannover Medical School, Germany under the
German title “Stosswellentherapieu n dK r a f t t r a i n i n g
zur Therapie der Cellulite - eine randomsiert-kontrol-
lierte Studie” (Nr. 5206). The study is registered at
ClinicalTrials.gov with ClinicalTrials.gov identifier:
NCT00947414.
Design of the study
(CONSORT Item 3a)
This is a single-center superiority randomised-controlled
trial with a 1:1 parallel group randomisation
Setting of the study
(CONSORT Item 4b)
This study took place at the Hannover Medical School,
Germany in the department for Plastic, Hand and
Reconstructive Surgery starting in June 2009. Hannover
Medical School is a University Hospital with 7040
employees, among them 1221 physicians and 2839 med-
ical students. In 2009, 1444 clinical beds achieved 54628
stationary cases with a 90% bed occupancy rate. This
trial is a single center randomised-controlled trial.
Hannover had on June 30, 2009 a population of 519212
people with 272541 females accounting for 51.8%. 77,378
people were aged below 18 (14,7%), 128,855 60 years or
older (24.5%). Uncontrolled prevalence report estimate
up to 85% of females suffering from cellulite of various
degrees. This elaboration provides some further informa-
tion whether the settings and locations used in this study
are relevant for another given avid reader in terms of
external validity, since the results obtained here do not
necessarily correlate to a different environment [10].
Participants
(CONSORT Item 4a)
Eligible patients were females aged 18 or over and 65 or
younger with cellulite who met the eligibility criteria
with documented cellulite 1°-4° according to the Nürn-
berger score. Exclusion criteria were suspected or evi-
dent pregnancy, no cellulite, no informed consent or age
under 18 years or above 65 years. Patients were
recruited by advertisements in local regional newspapers
and via the Internet. Some patients from the United
States used the http://www.ClinicalTrials.gov reference
to approach and seek for participation. Given the broad
inclusion criteria in terms of age (18-65 years) and
degree of cellulite (Nünberger score 1°-4°) we thought
to improve external validity, which is generalisability
[11]. Furthermore, in terms of gender, female partici-
pants are the minority of randomized-controlled trials
per se. An analysis of published RCTs from 1994 to
2006 revealed that patients were excluded for age in
72% and for female gender in 39% [12], which limits
external validity of a given RCT. Both, pre- and postme-
nopausal women are included with documentation of
their status and concomitant medication.
Table 1 Non-randomised clinical studies on the effect of extracorporeal shock wave therapy on cellulite with different
outcome measures applied
Author Journal Year Patient number Outcome Design
Angehrn F [4] Clin Interv Aging 2007 21 HR-Ultrasound Case series
Kuhn C [5] Clin Interv Aging 2008 1 HR Ultrasound, histopathology Case Study
Christ C [6] Aesthetic surgery journal 2008 59 Dermascan US
DermaLab System
Cohort study
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(CONSORT Item 5)
In CelluShock-2009 patients were randomly assigned
with a 1:1 ratio to either extracorporeal shock-wave
therapy with a 25-fold higher energy than the sham
extracorporeal shock wave therapy. Both groups addi-
tionally participated in a home-based daily gluteal thigh
exercise program (Figure 1 CONSORT flow chart).
￿ Intervention group:
◦ Six sessions of extracorporeal shockwave ther-
apy (every 1-2 weeks) with focussed shock waves
(2000 impulses, 0, 25 mJ/mm2)p l u sd a i l y
home-based gluteal strength exercise
￿ Control group:
◦ Six sessions of sham extracorporeal shock wave
(2000 impulses, 0, 01 mJ/mm2, every 1-2 weeks)
plus daily home-based gluteal strength exercise
Extracorporeal shock wave therapy was applied using
a STORZ focussed Duolith machine as acoustic wave
treatment. Acoustic wave are sound wave characterised
by high pressure in comparison to ambient pressure.
The generation of sound waves used for medical appli-
cation are generated extracorporeal, thus extracorporeal
acoustic wave therapy or shock wave therapy. As acous-
tic waves propagate according to the laws of acusto-
optics, any change in the acoustic properties might
cause an impedance jump at the border of tissues.
Energy will thus be released in the target tissue, such as
lymphangion contraction and improved permeability of
cellular membranes in terms of acoustic wave therapy.
In order to increase the motivation of the participating
females we added a daily home-based gluteal strength
exercise program. Twice a day (in the morning and the
evening) two different exercises were performed with 15
repetitions for each leg (Figures 1a/b, 2a/b).
The daily workup was noted in a exercise log to
improve participants’ compliance.
This elaboration was that detailed in order to provide
the reader with sufficient detail to replicate the interven-
tion in a similar fashion [13] and to meet the CON-
SORT recommendations for reporting of randomised
trials of non-pharmacologic treatment [14].
Primary and secondary outcome measures
(CONSORT Item 6a)
The primary endpoint with respect to efficacy of the
combined extracorporeal shock wave therapy and gluteal
strength exercises vs. sham extracorporeal shock wave
therapy and the same gluteal strength exercise program
was the change on digital photographs.
Given the recent publication of a photonumeric sever-
ity score [15] providing reliable, comprehensive, and
reproducible severities from 0 to 15 we added this tool
in 2009 during the recruiting phase in contrast to the
initially proposed Nürnberger and Müller score docu-
mented in the ClinicalTrials.gov file. This 4-graded scale
will be additionally determined by two independent
blinded assessors.
4-graded scale according to Nürnberger and Müller [16]
￿ Stage 0: No dimpling when the skin is pinched
￿ Stage I: No spontaneous displays of alterations,
pressure is required to show dimpling
￿ Stage II: Dimpling is visible when standing, not
while lying
￿ Stage III: Skin alterations while both standing and
lying
The classification was performed based on standar-
dized photographs taken by a professional medical
photographer at baseline and after 12 weeks after rando-
misation in both groups. The assessment of the anon-
ymous digital images was carried out by two blinded
assessors who were not aware of either the study arm or
the fact that it is a baseline or a follow-up photograph
taken 12 weeks after study initiation.
In order to overcome the problems of interpretation
associated with multiplicity of analyses were decided to
choose the aforementioned clinical endpoint which is a
visual one as the primary endpoint and apparatively
derived results as secondary endpoints in CelluShock.
Secondary endpoints of CelluShock RCT were:
￿ Change of circumference of the thigh [cm]
￿ Microcirculatory change of capillary blood flow of
the thigh using combined Laser-Doppler & spectro-
photometry (Oxygen-to-see system, LEA Medizin-
technik, Germany, http://www.lea.de)
￿ Microcirculatory change of tissue oxygen satura-
tion of the thigh using combined Laser-Doppler &
spectrophotometry (Oxygen-to-see system, LEA
Medizintechnik, Germany, http://www.lea.de)
￿ Microcirculatory change of postcapillary venous
filling pressure of the thigh using combined Laser-
Doppler & spectrophotometry (Oxygen-to-see sys-
tem, LEA Medizintechnik, Germany, http://www.lea.
de)
￿ Skin elasticity using the Cutometer® (Cutometer
MPA 580, Kosmetik Konzept KOKO GmbH & Co
KG, Leichlingen, http://www.dermaviduals.de)
[17-20]
￿ Self-assessment of the success on a visual analogue
scale 0-10 (0 = no change, 10 = fully satisfied)
The combined laser Doppler flowmetry & spectrophoto-
metry system Oxygen-to-see (LEA Medizintechnik, http://
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mine three distinct parameters of tissue microcirculation
simultaneously in 2 and 8 mm tissue depths [21-26]:
￿ Capillary blood flow
￿ Tissue oxygen saturation
￿ Postcapillary venous filling pressures
All patients were measured at baseline and after 12
weeks regarding the primary and all secondary end-
points. Microcirculatory assessment was performed as
microcirculatory gluteal mapping on various standar-
dized locations (10 on each thigh) in a prone position.
Change of trial outcomes
(CONSORT Item 6b)
To date, during the recruiting phase of CelluShock there
h a sb e e nn oc h a n g ei na n yp r i m a r yo rs e c o n d a r yo u t -
come nor is it intended to change it.
Power calculation
(CONSORT Item7a)
To detect at least a change of one class in the four-
graded Nürnberger scale of cellulite with a two-sided 5%
significance with a 80% power a sample size of 50 parti-
cipants with an estimated drop-out rate of 15% was
calculated.
Figure 1 CONSORT patient flow chart.
Knobloch et al. BMC Women’s Health 2010, 10:29
http://www.biomedcentral.com/1472-6874/10/29
Page 4 of 7Interim analysis
(CONSORT Item 7b)
Due to the calculated rather short recruiting phase of
only 2 years and the 12-week follow-up, we do not plan
to perform an interims analysis. Furthermore, due to the
low if at all adverse effects reported for extracorporeal
shock wave therapy applied in our dosages we do not
expect that the trial has to be ended or stopped early
for ethical reasons.
Randomization
(CONSORT Item 8a)
For allocation of participants, a 1:1 ratio randomization
was performed using opaque envelopes for the conceal-
ment of allocation. In order to minimize the chance of
bias we used [27]
a) Opaque, sealed and serial numbered envelopes
b) opened sequentially and only after the partici-
pant’s name and further details were written on the
envelope
c) kept them in a locked and secure place.
(CONSORT Item 8b)
Participants were randomly assigned following simple
1:1 randomisation procedures using opaque and sealed
envelopes to one of the two study arms (interventional
or control arm) without any restriction.
(CONSORT Item 9)
The allocation sequence was concealed from the
researcher (BJ) enrolling and assessing participants in
sequentially numbered, opaque, sealed envelopes [28].
Allocation sequence
(CONSORT Item 10)
Sequentially numbered, opaque and sealed envelopes
were opened by one researcher (BJ) after the partici-
pants was deemed appropriate fulfilling all inclusion cri-
teria and no exclusion criteria as stated above.
Blinding
(CONSORT Item 11a)
Blinding was achieved for all participants enrolled in the
trial, the photograph taking the digital images for the
primary outcome measure, the two assessors of the out-
come measures, all additional health care providers and
for the analyst from the biometrical department. Only
one researcher (BJ) was aware of the group assignment
performing the randomisation and the extracorporeal
shock wave therapy. As stated above, the extracorporeal
shock wave therapy was applied in both groups (inter-
vention and control group) with an identical number of
impulses (2000 per thigh) and the same frequency (4
Hz), thus the time of the procedure was identical. Only
the energy of either 0,25 mJ/mm2 or 0,01 mJ/mm2
applied was different between both groups, which were
hidden from the patient displayed on the STORZ Duo-
lith console. Thus, only the operator of the shock wave
console (BJ) was aware which energy to chose.
The assessment of the primary and secondary out-
comes was performed by blinded assessors indepen-
dently from each other without any clue whether the
digital image displayed was before or after therapy or
with group (intervention or control group) was rando-
mised. In addition, no patient was aware whether he
was in the intervention or the control group, since all
underwent similar shock wave therapy over the same
period, however, with a 25-fold delta in energy.
Similarities of interventions
(CONSORT Item 11b)
As stated above, the extracorporeal shock wave therapy
was applied in both groups (intervention and control
group) with an identical number of impulses (2000 per
thigh) and the same frequency (4 Hz), thus the time of
the procedure was identical. Only the energy of either
0,25 mJ/mm2 or 0,01 mJ/mm2 applied was different
between both groups, which were hidden from the
patient displayed on the STORZ Duolith console. Thus,
only the operator of the shock wave console (BJ) was
aware which energy to chose.
Compliance to the extracorporeal shock wave therapy
was naturally measured. In terms of compliance to the
daily suggested gluteal thigh strength exercises, a daily
log was recorded over the 12 weeks in addition to serial
interviews with the participants throughout the trial
Figure 2 First exercise (15 repetitions per leg twice a day over
12 weeks).
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strength program.
As the CONSORT 2010 statement does not include
any longer the suggestion to obtain information what
the participants randomised thought which group they
were at the end of the trial, we do not record this item
[29].
Statistics
(CONSORT Item 12a)
The primary endpoint was change of Nürnberger scale
assessed on digital standardised photographs by two
independent expert examiners. An intention-to-treat
analysis was applied that once randomised the patients
is retained in the allocated group (intervention group or
control group) for analysis whatever occurs. This is to
limit bias in this superiority RCT.
CONSORT flow chart
Figure 3 highlight the proposed patient flow throughout
the CelluShock-2009 randomised trial (Figure 3).
Discussion
Given the aforementioned clinical trials applying extra-
corporeal shockwave therapy in females suffering from
c e l l u l i t ew es e e kt oe v a l u a t ei nal a r g er a n d o m i s e d - c o n -
trolled trial the effects of strength training and the
additional effect of shockwave therapy on the degree of
cellulite. While to date only one small size randomised
controlled trial [7] with wide confidence intervals has
been published, we try to overcome the methodological
Figure 3 First exercise (15 repetitions per leg twice a day over
12 weeks).
Figure 4 Second exercise (15 repetitions per leg twice a day
over 12 weeks).
Figure 5 Second exercise (15 repetitions per leg twice a day
over 12 weeks).
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date, there is no information whether gluteal strength
training is effective in a clinical trial in cellulite, which
we will elaborate on. Furthermore, the superiority of
additional extracorporeal shockwave therapy in addition
to daily gluteal strength training in females suffering
from cellulite will be the research question to be
answered by this RCT.
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